Acrivon Therapeutics, Inc. (ACRV)
2.10
+0.04
(+1.94%)
USD |
NASDAQ |
Aug 31, 16:00
2.05
-0.05
(-2.38%)
After-Hours: 20:00
Acrivon Therapeutics Shareholders Equity (Quarterly) : 86.66M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 86.66M |
| March 31, 2026 | 95.52M |
| December 31, 2025 | 112.52M |
| September 30, 2025 | 128.60M |
| June 30, 2025 | 143.04M |
| March 31, 2025 | 160.39M |
| December 31, 2024 | 176.79M |
| September 30, 2024 | 196.89M |
| June 30, 2024 | 216.06M |
| March 31, 2024 | 107.98M |
| Date | Value |
|---|---|
| December 31, 2023 | 121.20M |
| September 30, 2023 | 138.15M |
| June 30, 2023 | 149.18M |
| March 31, 2023 | 160.47M |
| December 31, 2022 | 170.48M |
| September 30, 2022 | 76.90M |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | -23.81M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 99.09M |
| Total Liabilities (Quarterly) | 12.43M |
| Debt to Equity Ratio | 0.0244 |
| Current Ratio | 7.993 |
| Net Debt Paydown Yield | 0.37% |